ArticleMicrobiology spectrum2026
Clinical application of BALF-mNGS in immunocompromised and immunocompetent patients with suspected invasive pulmonary aspergillosis: differentiating infection from colonization, microbiome features, and clinical impact.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Invasive pulmonary aspergillosis (IPA) not only causes high morbidity and mortality, especially in immunocompromised patients, but also occurs in immunocompetent individuals. Differentiating infection from colonization is challenging, and bronchoalveolar lavage fluid metagenomic next-generation sequencing (BALF-mNGS) may aid diagnosis, microbiome profiling, and clinical assessment. We retrospectively analyzed patients with suspected IPA who underwent BALF-mNGS between December 2021 and March 2025. Patients were classified by immune status. IPA diagnosis was based on EORTC/MSGERC 2020 criteria in immunocompromised patients, while immunocompetent cases were adjudicated using an integrated clinical, radiological, and microbiological assessment. A total of 178 patients were finally included and classified according to immune status into an immunocompromised group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.